Eurobio Scientific Société anonyme (ALERS.PA)
Paris · EUR · Healthcare · Medical Devices
€26.40 (+4.35%) as of
Key statistics
- Market cap
- 265.80M
- P/E (TTM)
- 37.71
- Forward P/E
- 23.36
- EPS (TTM)
- 0.70
- Dividend yield
- 0.00%
- 52-week range
- 19.20 – 26.50
- Beta
- 0.59
- Revenue (TTM)
- 172.26M
- Profit margin
- 4.18%
- Analyst target
- €30.00
- Volume
- 4.34k
About Eurobio Scientific Société anonyme
Eurobio Scientific Société anonyme engages in research, development, and marketing specialty diagnostic products in the areas of transplantation, infectious diseases, autoimmunity, oncology, and life sciences. The company produces and markets transport and preservation media for corneal grafts; AlloMap, for heart transplant follow up; cell culture media, molecular biology reagents, contract manufacturing service, and proprietary antibodies; TQS (Tetanus Quick Stick), a rapid test used in emergency departments or pharmacies to assess the vaccination status or immune protection of patients against tetanus; EBX molecular biology ranges in the field of infectious diseases; and EndoPredict range, a second-generation multigene expression test for postmenopausal women with early-stage breast cancer, ER positive, and HER2 negative, as well as Prolaris. It also provides GenDx, EurobioPlex, FungiLine, Biosafety PKA, and immunology products. The company was formerly known as Diaxonhit and changed its name to Eurobio Scientific Société anonyme in June 2018. Eurobio Scientific Société anonyme was incorporated in 1997 and is headquartered in Les Ulis, France.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- Les Ulis, France
- Employees
- 443
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.